Clinical trials
HER2 Positive clinical trials
Below are recruiting her2 positive clinical trials, each written for real people, not researchers. We’re tracking 346 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06234137Recruiting
Chemo plus targeted therapy for advanced HER2+ breast cancer
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
Wenzhou, ZhejiangAges 18–75 - NCT07281001Recruiting
Trastuzumab deruxtecan study for breast cancer patients
This study looks at how well the drug trastuzumab deruxtecan works in women with breast cancer that has spread. It is for patients who have already taken this drug.
MoscowAges 18–80 - NCT05982678RecruitingPhase 2
Study of a drug for breast cancer that has spread to a few spots
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
AmsterdamAges 18 years+ - NCT07741448RecruitingPhase 2
Chemo and targeted drug before surgery for HER2-positive upper tract cancer
This trial tests a combination of chemotherapy (gemcitabine) and a targeted drug (Trastuzumab Rezetecan) before surgery to remove the kidney and ureter. It may help shrink the tumor and improve outcomes for people with HER2-positive upper tract urothelial cancer.
Huanggang, HubeiAges 18–75 - NCT06821490Enrolling by invitation
TAD biopsy for HER2+ breast cancer with positive lymph nodes
This trial tests the accuracy of a targeted axillary dissection (TAD) after chemotherapy in people with HER2+ breast cancer that has spread to the lymph nodes. It aims to see if the TAD method can correctly identify which lymph nodes are cancer-free before surgery.
Valencia, ValenciaAges 18 years+ - NCT07263425RecruitingPhase 2
Study of thiotepa and trastuzumab for breast cancer that spread to the lining of the brain and spinal cord
This trial tests a combination of two drugs given through a special port in the head to treat HER2-positive breast cancer that has spread to the layer covering the brain and spinal cord (leptomeningeal metastasis). It aims to see if this treatment is safe and effective.
Nanjing, JiangsuAges 18–75 - NCT05890287Recruiting
Chidamide plus hormone therapy after chemotherapy for breast cancer
This trial studies chidamide added to standard hormone (endocrine) therapy to help prevent breast cancer from coming back after initial chemotherapy. It may help by keeping cancer under control for longer in people with HR-positive, HER2-negative breast cancer who respond to first-line treatment.
TianjinAges 18–75 - NCT05856383Recruiting
HER2-positive metastatic breast cancer drug combination study
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
Hangzhou, ZhejiangAges 18 years+ - NCT07296705RecruitingPhase 2
New drug combo to save the bladder in HER2-positive bladder cancer
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
Fuzhou, FujianAges 18–85 - NCT06557057Recruiting
Aromatase inhibitors and diabetes risk in breast cancer
This study looks at how aromatase inhibitors, a type of hormone therapy for breast cancer, affect blood sugar and diabetes risk. It compares women taking these drugs to those on tamoxifen or healthy women, to see if there are changes in glucose control.
Rochester, MinnesotaAges Any age - NCT06481956Enrolling by invitationPhase 2
T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Hangzhou, ZhejiangAges 18–75 - NCT07152405RecruitingPhase 3
New drug vs. chemo for HER2+ stomach cancer
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that has spread. The goal is to see if BL-M07D1 works better than standard chemo.
Harbin, HeilongjiangAges 18–75 - NCT07205822RecruitingPhase 3
Dato-DXd for advanced HR-positive, HER2-negative breast cancer
This trial tests a new drug called Dato-DXd for people with a specific type of breast cancer that is hormone receptor-positive and HER2-negative (IHC 0). It's for those whose cancer has stopped responding to hormone therapy and who haven't had chemotherapy for cancer that has spread.
Largo, FloridaAges 18 years+ - NCT05256225RecruitingPhase 3
Adding Herceptin medicines to chemo for HER2-positive endometrial cancer
This Phase 3 trial tests whether adding Herceptin Hylecta or Phesgo to standard chemotherapy works better than chemotherapy alone for HER2-positive serous endometrial cancer or carcinosarcoma. It may help by improving how well treatment controls or shrinks the cancer.
Birmingham, AlabamaAges 18 years+ - NCT04360941RecruitingPhase 1
Test drug combo for metastatic breast cancer with AR-positive type
This Phase 1 trial tests palbociclib (a pill) plus avelumab (an IV antibody) for people with metastatic or hard-to-remove locally advanced breast cancer that is AR-positive but otherwise triple-negative. The goal is to see if the treatment is safe and potentially effective for this specific cancer subtype.
Manchester, Greater ManchesterAges 18 years+ - NCT07704177RecruitingPhase 2
A study of trastuzumab rezetecan plus two other drugs for advanced bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT03383978RecruitingPhase 1
Test brain injections plus IV antibody for HER2-positive glioblastoma
This early-phase study tests a combination of cells injected directly into the brain and an IV antibody to treat recurrent HER2-positive glioblastoma (or a related tumor, gliosarcoma). It may help by attacking the tumor locally in the brain while the antibody boosts the immune system’s response.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT04383275RecruitingPhase 2
De-escalation trial for early HER2+ breast cancer
This Phase 2 study tests whether people with early-stage HER2-positive breast cancer may be treated with less intensive therapy, without losing effectiveness. You may be considered if your tumor is small, lymph nodes are negative, and your hormone (ER/PR) status and HER2 test results match the study groups.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
San Francisco, CaliforniaAges 18 years+ - NCT04899908RecruitingPhase 2
Brain radiation with or without gadolinium nanoparticles for brain metastases
This trial tests whether adding tiny gadolinium-containing nanoparticles to standard brain radiation can better control brain metastases from certain cancers. It is for people with tumors that have grown after immunotherapy, are from certain cancers (like melanoma, GI, or HER2+ breast), are cystic, are large, or have come back after prior radiation.
Boston, MassachusettsAges 18 years+ - NCT05150691RecruitingPhase 1/Phase 2
Early study of an HER2 drug in advanced solid tumors
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
Cerritos, CaliforniaAges 18 years+ - NCT05187832RecruitingPhase 1
Study drug for ER-positive, HER2-negative breast cancer in postmenopausal women
This Phase 1 trial tests AND019, a new study drug, in postmenopausal women with advanced or metastatic ER-positive and HER2-negative breast cancer. It aims to see if the drug is safe and can control the cancer when other standard treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT05292742RecruitingPhase 2
Continue targeted breast cancer therapy or switch to a new combo
This Phase 2 study compares two treatment plans after breast surgery when cancer did not fully disappear before surgery. It tests whether adding trastuzumab, pyrotinib, and capecitabine works better than continuing the original targeted therapy.
Fuzhou, FujianAges 18–75 - NCT05427383RecruitingPhase 2/Phase 3
KN026 plus chemo for HER2-positive stomach cancer after first treatment failure
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
BeijingAges 18 years+
Hear when a new HER2 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive?
- Yes. Clin2 currently lists 346 recruiting her2 positive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.